About
Antibody Therapeutics
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibody
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
4
As Collaborator
1
Total Enrollment
234
By Phase
PHASE1/PHASE2: 2PHASE1: 3
By Status
COMPLETED: 3RECRUITING: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT05934539Collaborator
ALG.APV-527 First-in-human Study
PHASE1/PHASE2Recruiting
56 participants
Started: Dec 23, 2022 · Completed: Dec 1, 2025
NCT04888312Lead Sponsor
Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients
PHASE1/PHASE2Active, not recruiting
94 participants
Started: Sep 17, 2021 · Completed: Jun 30, 2026
NCT04144842Lead Sponsor
Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017
PHASE1Completed
27 participants
Started: Dec 3, 2019 · Completed: Mar 29, 2023
NCT03782467Lead Sponsor
Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015
PHASE1Completed
33 participants
Started: Jan 30, 2019 · Completed: Mar 3, 2021
NCT02379741Lead Sponsor
ADC-1013 First-in-Human Study
PHASE1Completed
24 participants
Started: Apr 30, 2015 · Completed: Mar 8, 2017
Funding History (1)
D
Oct 1, 2015
Locations (1)
Headquarters
Lund, Sweden
Map
Loading map...